Vlad Coric, M.D.
Chief Executive Officer and Director
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma…
Robert Berman M.D.
Chief Medical Officer
Dr. Berman has over 30 years of experience in neuroscience research, both within academia and industry. At the Yale University School of Medicine, he held clinical and research positions at the Connecticut Mental Health Center and the West Haven VA Medical Center. While on faculty at Yale, his work focused on translational research and novel treatments for affective disorders. This work includes the first report…
Chief Financial Officer
Mr. Engelhart brings to Biohaven 30 years of finance experience including over 17 years within the pharmaceutical industry at Alexion Pharmaceuticals, Bristol-Myers Squibb and Schering-Plough. He joins Biohaven from Alexion Pharmaceuticals where he was Executive Director, Finance of the North America and Latin America Regions, providing financial leadership, strategy…
Elyse Stock, M.D.
Chief of Portfolio Strategy and Development
Dr. Stock has 30 years of clinical and drug development experience. After practicing psychiatry for 11 years she joined the pharmaceutical industry. Within the industry, Dr. Stock has spent the last 19 years at Bristol-Myers Squibb developingnumerous experimental agents across multiple therapeutic areas including…
Charlie Conway, Ph.D.
Chief Scientific Officer
Dr. Conway has 28 years of research experience examining the biology of pain mechanisms, including 17 years of pharma experience in drug discovery and development in positions of increasing responsibility at Bristol-Myers Squibb Company (BMS). Dr. Conway led BMS’s biology program efforts on the CGRP receptor antagonist for over 10 years and was part of the development team advancing rimegepant into the clinic…
Robert Croop, M.D.
Chief Development Officer – Neurology
Dr. Croop brings to Biohaven over 25 years of clinical drug development experience in a wide range of neuroscience programs. Board certified in Neurology by the American Board of Psychiatry and Neurology, he entered the pharmaceutical industry at DuPont Merck Clinical Research and Development. After joining Bristol-Myers Squibb through its acquisition of DuPont Pharma, he led a group responsible for First in Human, Phase I, and…
Donnie McGrath, M.D. MPH
Chief of Corporate Strategy and Business Development
Dr. McGrath has over 22 years of clinical research and pharmaceutical business development experience. From 2013 to 2017, he was Vice President, Business Development, and Head of Search & Evaluation at Bristol-Myers Squibb, based in Princeton, NJ. During this period, the business development group…
Chief Commercial Officer
Mr. Tilton has over 20 years of experience commercializing drug products and leading global pharmaceutical business units. He joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful…
Vice President of Operations
Ms. Gentile has more than 26 years experience in the pharmaceutical industry in all phases of clinical research from Phase 1 through Phase 4, predominantly in the areas of psychiatry and neurology. She has deep, hands-on experience in most…
Douglas G. Gray, Esq.
Mr. Gray is a partner at Locke Lord LLP, a global law firm with over 1,000 lawyers in 23 offices (Corporate and Transactional Department) and concentrates his practice in areas of mergers, acquisitions, corporate governance, strategic alliances, and commercial ventures. He acts as general outside counsel to a number of clients, ranging from large multi-national companies…
Executive Director, Clinical Operations
Director, Clinical Operations
Associate Director, Clinical Operations
Senior Clinical Trial Lead
Senior Clinical Trial Lead
Clinical Trial Lead
Clinical Trial Lead
Clinical Trial Associate
Vice President of Regulatory Affairs
Ms. Frost has over 20 years of drug development experience with 17 years in various roles within Regulatory Affairs. Her experience spans all phases of drug development from preclinical research through Phases 1-3 and marketed products. Her numerous successful health authority interactions globally include approval of a new drug application for Daklinza and Abilify sNDAs…
Executive Administrative Assistant
Dave Stock, Ph.D.
Executive Director, Biostatistics